Treatment of Sarcoidosis

@article{Baughman2015TreatmentOS,
  title={Treatment of Sarcoidosis},
  author={R. Baughman and E. Lower},
  journal={Clinical Reviews in Allergy \& Immunology},
  year={2015},
  volume={49},
  pages={79-92}
}
In general, sarcoidosis treatment should be offered to palliate symptoms and improve quality of life or to prevent end-organ disease. Symptoms include pulmonary as well as extra-pulmonary manifestations of the disease. The assessment of response to disease includes functional studies such as the forced vital capacity. Radiologic imaging such as chest x-ray has also been used to assess response, although standardized measures have rarely been tested. There are sufficient clinical trials to make… Expand
Refractory Sarcoidosis: A Review
TLDR
Refractory sarcoidosis is considered as a disease in which second-line treatments are not sufficient to achieve satisfying disease control or satisfying corticosteroids tapering, and Methotrexate is the only first-line immunosuppressant validated by a randomized controlled trial. Expand
Current Medical Therapy for Sarcoidosis
TLDR
Anti‐inflammatory drugs limiting the pathologic impact of sarcoidosis in reducing enhanced immunity reactions, granulomatous formation, and their consequences and non anti‐inflammatory treatments, such as implantable cardiac devices, are also useful, particularly for some organs. Expand
Sarcoidosis of the central nervous system: Safety and efficacy of treatment, and experience of biological therapies
  • D. Kidd
  • Medicine
  • Clinical Neurology and Neurosurgery
  • 2020
TLDR
Evidence is provided that the use of high dose immunosuppression and early and prolonged use of biological therapies is associated with greatly improved outcomes and lower mortality in neurosarcoidosis. Expand
Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art
TLDR
This review is a state of the art of clinical presentations and immunological features of sarcoidosis, and the current therapeutic approaches used to treat the disease. Expand
Studies of different clinical manifestations of Sarcoidosis and the role of genetic factors
TLDR
The HLA-DRB1*04 allele is associated with an increased risk for involvement of the eyes, parotid and/or salivary glands and cranial nerves in sarcoidosis patients, and an increased CD4/CD8-ratio in enlarged LNs is not diagnostic for sarCOidosis in comparison to BALF, which indicates an airborne antigen as the triggering factor. Expand
Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study.
TLDR
MTX as a single agent in the treatment of sarcoidosis has proved to be a safe and effective steroid alternative and selected patients with chronic pulmonary sarcoIDosis experience definite PFT improvements after MTX treatment. Expand
Pulmonary Sarcoidosis Considerations in Primary Care
TLDR
It is shown that pharmacologic treatment of pulmonary sarcoidosis should depend on patient-specific symptomology and be individually customized, and tailor pharmacotherapy to meet the needs of each patient while basing treatment on current evidence allows for the delivery of optimal patient care. Expand
[Current Therapeutic Approaches to Sarcoidosis].
TLDR
A current stepwise therapeutic algorithm to sarcoidosis that characterizes additive and alternative therapeutic agents is given in the following review. Expand
Sarcoidosis: a rheumatologist’s perspective
  • S. Kobak
  • Medicine
  • Therapeutic advances in musculoskeletal disease
  • 2015
TLDR
There are studies showing that sarcoidosis may mimic the clinical and laboratory findings of these disorders, and nonsteroidal anti-inflammatory drugs and corticosteroids are used for treating the symptoms of rheumatologic findings. Expand
Distinguishing Blau Syndrome from Systemic Sarcoidosis
TLDR
This paper reviews the similarities and differences between Blau syndrome and Sarcoidosis and discusses the importance of distinguishing between them, particularly with regard to prognosis and outcomes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Established and experimental medical therapy of pulmonary sarcoidosis
TLDR
The goal of this review is to discuss the standard treatments for pulmonary sarcoidosis, including glucocorticoids, and cytotoxic agents, and compare them to the newer biological agents, such as infliximab and adalimumab, and discuss some novel treatments which are currently being evaluated. Expand
Rituximab in the treatment of refractory pulmonary sarcoidosis
TLDR
This study sought to evaluate the utility of B-cell depletion using rituximab in patients with refractory pulmonary sarcoidosis with a prospective, open-label, phase I/II trial. Expand
The treatment of sarcoidosis
TLDR
A trial of prednisone therapy in a small number of patients with disease restricted to the mediastinal and hilar nodes (Stage I) suggests thatprednisone treatment in this form of sarcoidosis may minimize dissemination and progression. Expand
An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment.
TLDR
The use of corticosteroids for pulmonary sarcoidosis is described in terms of six phases: initial high doses to control inflammation; tapering to a maintenance dose that will continue to suppress the inflammation but lessen the risk of Corticosteroid toxic reactions; continuing to receive the maintenance dose until a decision to taper off corticosterone is made; and treatment if relapse occurs. Expand
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.
TLDR
After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. Expand
Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis.
TLDR
Azathioprine may provide a safe alternative to corticosteroids when a steroid-sparing effect is required, but it is unlikely to be effective in patients who fail to respond to high dose cortICosteroids and/or have radiographic evidence of significant fibrosis. Expand
Outcome of the treatment for sarcoidosis.
TLDR
The use of corticosteroids was limited to those patients who had objective evidence of recent deterioration in lung function or serious extrapulmonary disease and those patients with sarcoidosis fulfilling these criteria were treated with cortiosteroids. Expand
Pentoxifylline in treatment of sarcoidosis.
TLDR
Results suggest that POF may improve therapeutic regimens in pulmonary sarcoidosis either by sparing or replacing corticosteroid therapy, and pentoxifylline (POF), which exerts TNF-inhibitory activity, as a therapeutic agent in active pulmonary sarCOidosis. Expand
Neurological complications of sarcoidosis
  • B. Stern
  • Medicine
  • Current opinion in neurology
  • 2004
TLDR
Neurosarcoidosis can be ‘staged’ with the use of neurodiagnostic testing and diagnosed with varying degrees of certainty and treatment should be approached within the context of the anticipated clinical course of the patient, avoidance of adverse drug effects, and from the perspective of the comprehensive management of a chronic disease. Expand
Treatment of sarcoidosis with infliximab.
TLDR
Infliximab appears to be an effective, safe treatment for patients with refractory sarcoidosis, including such manifestations as lupus pernio, uveitis, hepatic sarcoidsosis, and neurosarcoidotic disorders. Expand
...
1
2
3
4
5
...